Trials / Completed
CompletedNCT00380367
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 9 Years – 15 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India. Quadrivalent HPV Vaccine is composed of L1 virus-like particles (VLPs) from HPV types 6, 11, 16, and 18.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6. |
Timeline
- Start date
- 2007-05-03
- Primary completion
- 2008-02-04
- Completion
- 2008-02-04
- First posted
- 2006-09-26
- Last updated
- 2023-05-31
- Results posted
- 2009-04-14
Source: ClinicalTrials.gov record NCT00380367. Inclusion in this directory is not an endorsement.